Cannasoul R&D Ltd.
Pioneer in cannabis research, analytics, and evidence-based therapeutics development.
Website: https://www.cannasoul.co.il
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Cannasoul R&D Ltd. |
| Tagline | Pioneer in cannabis research, analytics, and evidence-based therapeutics development. |
| Headquarters | Herzliya, Israel |
| Founded | 2018 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Middle East / North Africa |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion) |
| Funding Label | Undisclosed |
Links
PUBLIC
- Press release (InterCure x Cannasoul): https://www.globenewswire.com/news-release/2025/11/03/3179258/0/en/InterCure-and-Cannasoul-Sign-Strategic-Investment-and-Collaboration-Agreements-to-Advance-Cannabis-Science-and-Pharmaceutical-Innovation.html
- Israeli accreditation registry listing: https://www.israc.gov.il/?pg=lab&categoryid=246&articleid=271
- Crunchbase profile (funding round): https://www.crunchbase.com/funding_round/cannasoul-analytics-series-unknown--789a4299
- PitchBook profile: https://pitchbook.com/profiles/company/491282-74
Executive Summary
PUBLIC
Cannasoul R&D Ltd. is a Herzliya-based cannabis research and analytics company that has spent seven years building the kind of regulated laboratory infrastructure and academic IP the cannabis sector has historically lacked. It is now being pulled into a much larger commercial vehicle through a November 2025 investment by Israel's largest licensed medical cannabis operator, InterCure Ltd. [GlobeNewswire, Nov 2025]. Founded in 2018 as a spinout co-formed by the Technion Research & Development Foundation and Prof. Dedi Meiri, the company sits at an unusual intersection of accredited analytical chemistry, cell-based screening through its MyPlant-Bio subsidiary, and translational therapeutics development [StreetInsider] [Health Europa, Jul 2020]. Its analytics arm operates under ISO/IEC 17025 accreditation and GCLP, supervised by the Israel Health Ministry's Cannabis Unit (Yakar), which positions it as one of a small number of facilities globally able to support clinical-grade cannabis research [Neoteryx]. The InterCure agreement, which begins with an initial 28% ownership stake and an option to scale to 51%, is paired with the formation of a Scientific Advisory Board chaired by Prof. Meiri [StockTitan, Nov 2025]. Prior backers include TAO Synergies and Synaptogenix, the latter having taken a position in the analytics entity [Crunchbase] [StreetInsider]. The commercial thesis hinges on translating Meiri's Technion lab output into prescribable products, with breast cancer, sleep disorders, and a terpene-plus-CBD anti-inflammatory program developed with Eybna among the disclosed pipelines [GC Intelligence] [Health Europa, Jul 2020]. Investors should watch for completion of the InterCure stake, the structure of the Scientific Advisory Board's first programs, and any movement on U.S. cannabis rescheduling, which the parties have publicly cited as a catalyst for international cannabis pharma [Yahoo Finance, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StockTitan, StreetInsider, and Health Europa.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech / Cannabis Therapeutics |
| Technology Type | Biotech / Life Sciences |
| Geography | Middle East / North Africa (Israel) |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (Technion) |
| Funding | Undisclosed |
Company Overview
PUBLIC
Cannasoul was formed in 2018 as a commercial vehicle around the cannabis research program of Prof. David (Dedi) Meiri at the Technion - Israel Institute of Technology, with the Technion Research & Development Foundation (TRDF) named as a co-founder of the analytics entity [StreetInsider]. The company is headquartered in Herzliya and operates through at least two distinct units that public sources reference by name: Cannasoul Analytics, the accredited testing and research laboratory, and MyPlant-Bio, a subsidiary focused on cell-based screening of plant extracts [Health Europa, Jul 2020] [Labguru]. The Israeli national accreditation body (ISRAC) lists Cannasoul R&D Ltd. as an accredited laboratory under registry number 473, consistent with the company's public claim of ISO/IEC 17025 status [ISRAC] [Neoteryx].
The company's first widely covered commercial milestone came in April 2020, when it announced a research collaboration with Israeli terpene formulator Eybna to study a proprietary terpene blend, NT-VRL, as a potential modulator of the cytokine storm associated with severe viral infections [Markets Insider, Apr 2020]. By July 2020, the partners reported initial in-vitro results suggesting that the NT-VRL formulation combined with CBD produced higher inhibition of relevant pro-inflammatory cytokines than the corticosteroid comparator used in the assay, a finding picked up by Forbes and Health Europa [Forbes, Jul 2020] [Health Europa, Jul 2020]. A subsequent capital event saw Synaptogenix, a Nasdaq-listed clinical-stage biotech, acquire a significant stake in Cannasoul Analytics [StreetInsider]. Israeli growth-equity firm TAO Synergies is also recorded by Crunchbase as a participant in a prior venture round [Crunchbase].
The most consequential milestone is the November 3, 2025 signing of definitive share purchase and collaboration agreements with InterCure Ltd. (Nasdaq/TASE: INCR), Israel's largest licensed producer of medical cannabis. Under the disclosed terms, InterCure takes an initial 28% stake with an option to increase to 51%, Prof. Meiri is expected to chair InterCure's newly constituted Scientific Advisory Board, and the parties will jointly pursue research, development, and commercialization of evidence-based cannabis therapeutics [GlobeNewswire, Nov 2025] [StockTitan, Nov 2025]. The deal is positioned by both companies as a response to the U.S. administration's reported review of cannabis rescheduling from Schedule I to Schedule III [Yahoo Finance, Nov 2025].
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StockTitan, ISRAC, and StreetInsider.
Product and Technology
MIXED
Cannasoul's product surface area is narrower and more scientifically specific than most cannabis companies that reach press coverage, and it is best understood as three connected layers. The first is the analytics laboratory: Cannasoul Analytics is described in third-party documentation as GCLP approved, ISO/IEC 17025 accredited, and operating under the supervision of the Israel Health Ministry's Cannabis Unit (Yakar) [PUBLIC] [Neoteryx]. That accreditation status is independently visible on the Israeli national accreditation registry [PUBLIC] [ISRAC]. In practical terms, this means the lab is qualified to support potency testing, contaminant screening, pharmacokinetic studies, and pre-clinical and clinical trial sample analysis, the kind of work that pharmaceutical sponsors require before regulators will accept data.
The second layer is MyPlant-Bio, a subsidiary that has built what one published profile describes as a library of cell-based models used to screen plant extracts for biological effect [PUBLIC] [Labguru]. Coupled with Prof. Meiri's published work cataloguing cannabis chemovars, this gives the group an internal pipeline for matching specific plant chemistries to disease-relevant cellular endpoints, an approach that differs from the more common industry pattern of screening isolated cannabinoids in a single indication. The third layer is the therapeutic programs themselves. Public sources name breast cancer and sleep disorders among the indications under investigation [PUBLIC] [GC Intelligence], and the Eybna NT-VRL collaboration remains the most documented program, with reported in-vitro evidence that adding CBD to the terpene blend yielded the highest cytokine inhibition observed in the study [PUBLIC] [Health Europa, Jul 2020].
What is not publicly disclosed is the patent estate, the stage of any regulatory submission, and whether any of the therapeutic programs have entered formal clinical trials in humans. Investors evaluating the platform should treat the analytics arm as the closest thing to a revenue-generating asset today, and the therapeutic programs as discovery-to-pre-clinical stage assets whose value depends heavily on the InterCure partnership's ability to fund and route them toward registration.
Data Accuracy: GREEN -- Confirmed by Neoteryx, ISRAC, Labguru, and Health Europa.
Market Research and Opportunity
PUBLIC
Cannabis therapeutics sits at a regulatory hinge point that, if it tips, would reprice every credible research-stage asset in the category. The thesis driving the InterCure transaction is explicit on this point: both parties cited the Trump administration's reported review of moving cannabis from Schedule I to Schedule III in U.S. federal law as a potential inflection for international cannabis companies [GlobeNewswire, Nov 2025] [Yahoo Finance, Nov 2025]. A move to Schedule III would not legalize recreational use federally, but it would remove the Section 280E tax penalty for U.S. operators, ease research approvals, and, most importantly for a company like Cannasoul, open a clearer path for cannabinoid-based prescription products to be developed under standard FDA pathways.
Independently sized TAM figures specific to Cannasoul's addressable segments are not present in the cited research, so the most honest framing is to triangulate from adjacent comparables. The U.S. What can be said with confidence is that InterCure itself is a publicly traded operator with disclosed access to advanced cultivation technology, AI-driven cultivation systems, and exclusive relationships with U.S. brands including The Flowery via its ISHI structure [StockTitan, Nov 2025], which gives Cannasoul's research output an immediate distribution and commercialization counterparty rather than a hypothetical one.
Demand drivers worth flagging: the persistent clinical interest in cannabinoids and terpenes for inflammation and oncology supportive care; the lack of accredited, regulator-supervised cannabis labs globally, which makes ISO/IEC 17025 status a scarce asset; and the willingness of listed biotech investors (Synaptogenix being one example) to take direct equity in Israeli cannabis research vehicles [StreetInsider]. The countervailing forces are equally clear: U.S. rescheduling has been reported as imminent multiple times across multiple administrations without resolution, and even a Schedule III outcome would leave most cannabis products outside the FDA approval pathway unless sponsors run the full clinical program.
| Market Anchor | Detail | Source |
|---|---|---|
| InterCure initial stake in Cannasoul | 28%, with option to 51% | [StockTitan, Nov 2025] |
| Regulatory catalyst cited by parties | Reported U.S. review of Schedule I to Schedule III | [Yahoo Finance, Nov 2025] |
| Lab accreditation | ISO/IEC 17025, GCLP, Yakar supervision | [Neoteryx] [ISRAC] |
The market case is less about Cannasoul addressing a measured TAM today and more about being one of a small number of qualified scientific assets positioned to capitalize if and when the U.S. regulatory window opens. The InterCure deal converts that optionality from a stand-alone bet into a partner-funded one.
Data Accuracy: YELLOW -- Regulatory and partnership claims confirmed by GlobeNewswire and StockTitan; sizing figures intentionally omitted for lack of cited third-party report.
Competitive Landscape
MIXED
Cannasoul does not compete in the consumer cannabis market; it competes for the position of "credible scientific partner" to operators, pharma sponsors, and regulators, and the field of qualified candidates is unusually thin.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Cannasoul R&D | Accredited cannabis analytics plus academic therapeutic pipeline | Seed; InterCure 28% stake (Nov 2025) | Technion-linked IP, ISO/IEC 17025 lab, MyPlant-Bio cell-based screening | [GlobeNewswire, Nov 2025] [Neoteryx] |
| Eybna | Terpene formulation R&D, botanical IP | Private, undisclosed | NT-VRL terpene blend; co-developer with Cannasoul on the antiviral program | [Markets Insider, Apr 2020] [Eybna] |
The segment map breaks into three groups. Incumbents in cannabis analytics are mostly regional testing labs serving state-licensed operators in the U.S. and provincial markets in Canada; few hold the combination of ISO/IEC 17025, GCLP, and a national health ministry's clinical-trial supervision that Cannasoul publishes [Neoteryx]. Challengers in cannabinoid therapeutics are dominated by a small set of public companies that have brought one or two cannabinoid drugs through formal regulatory approval and a longer tail of pre-clinical biotechs working on synthetic cannabinoids and reformulations. Adjacent substitutes include conventional pharma programs in the same indications, particularly in oncology supportive care and inflammation, where cannabinoid candidates must demonstrate either superior efficacy, better tolerability, or a meaningful cost advantage to win prescriber attention.
Where Cannasoul has a defensible edge today: the academic provenance of its pipeline through Prof. Meiri's Technion lab is not easily replicated, and the regulatory standing of the analytics arm functions as a quality moat that takes years to build. The InterCure relationship adds a distribution edge that pure research shops lack, including access to a licensed producer's cultivation, supply chain, and patient base [StockTitan, Nov 2025]. Where it is most exposed: Cannasoul does not operate its own commercial sales force, does not own a U.S. cultivation footprint, and has no disclosed FDA-stage clinical program of its own. A competitor that already holds an FDA-approved cannabinoid product has a structural lead that no amount of upstream science closes quickly.
The most plausible 18-month scenario: if U.S. rescheduling moves forward and InterCure exercises its option to increase its stake to 51%, Cannasoul effectively becomes the captive R&D engine of a vertically integrated cannabis pharma platform, and the named competitor most exposed is any analytics-only lab that lacks a commercial parent. The losing scenario: if rescheduling stalls and the InterCure option is not exercised, Cannasoul remains a high-quality but capital-constrained academic spinout whose therapeutic programs depend on third-party sponsors that may prefer to in-license rather than partner.
Data Accuracy: YELLOW -- Eybna relationship confirmed by Markets Insider and Health Europa; broader competitive map relies on category knowledge with limited public peer disclosure.
Opportunity
PUBLIC
The size of the prize, if Cannasoul executes against the InterCure partnership and the U.S. regulatory window opens, is the position of being the scientific backbone of the first vertically integrated international cannabis pharma platform.
In plain language, Cannasoul could become the in-house drug discovery and analytical infrastructure for a publicly traded cannabis operator that already has cultivation, distribution, and U.S. brand relationships in place. That is a materially different outcome than continuing as a stand-alone academic spinout. The cited evidence makes that outcome reachable rather than aspirational: InterCure has already paid for an initial 28% position with a contractual path to majority control, has agreed to stand up a Scientific Advisory Board chaired by Prof. Meiri, and has publicly framed the partnership as the mechanism through which it intends to access U.S. opportunity if rescheduling proceeds [GlobeNewswire, Nov 2025] [StockTitan, Nov 2025]. The structural ingredients for the outcome are in place; what is uncertain is timing and regulatory cooperation.
Growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Captive pharma R&D engine | InterCure exercises option to 51%, Cannasoul becomes consolidated R&D arm with funded clinical programs | InterCure option exercise within 24 months | Option is contractually defined and InterCure has publicly tied its U.S. strategy to Cannasoul science [GlobeNewswire, Nov 2025] |
| Rescheduling tailwind | U.S. moves cannabis to Schedule III, opening clearer FDA pathway and 280E relief for partners | Federal rescheduling decision | Both parties cited the reported review as the deal's strategic backdrop [Yahoo Finance, Nov 2025] |
| Analytics services scale-out | ISO/IEC 17025 lab wins contract research work from international pharma sponsors entering the category | Third-party sponsor signs multi-program contract | Lab is already accredited and supervised by Israel's Cannabis Unit, a credential most labs cannot match [Neoteryx] [ISRAC] |
The flywheel for a research-and-analytics platform is straightforward in principle: each clinical program run through the lab generates regulator-grade data, that data strengthens the IP estate, the IP estate attracts sponsor partnerships, and sponsor partnerships fund the next cycle of programs without diluting equity. The early evidence that this flywheel is starting to spin includes the prior Synaptogenix stake, the multi-year Eybna research relationship that produced published in-vitro results, and now the InterCure agreement, which converts a research lab into a strategic asset of a listed operator [StreetInsider] [Health Europa, Jul 2020] [GlobeNewswire, Nov 2025]. Each of those transactions raised the floor of credibility for the next.
A credible, conservative comparable is InterCure itself, which is publicly traded on Nasdaq and TASE and whose investment thesis is increasingly tied to international expansion into a potentially rescheduled U.S. market [StockTitan, Nov 2025]. If the captive R&D engine scenario plays out and Cannasoul's pipeline contributes one approvable cannabinoid therapeutic over a multi-year horizon, the value accrues primarily to InterCure shareholders, with Cannasoul's remaining minority equity riding the same curve (scenario, not a forecast). If instead the analytics services scale-out scenario plays out, the comparable is closer to a specialty contract research organization, a category where mid-tier players have historically been valued on recurring revenue multiples that reward accreditation and regulator relationships. Neither scenario requires Cannasoul to win a category alone, and that is the core of the opportunity: the upside cases are ones in which a partner does most of the commercial heavy lifting and Cannasoul supplies the scientific authority.
Data Accuracy: GREEN -- Confirmed by GlobeNewswire, StockTitan, Yahoo Finance, and Neoteryx.
Sources
PUBLIC
[Cannabis Business Times, Nov 2025] InterCure, Cannasoul Partner to Advance Cannabis Science, Pharmaceutical Innovation | https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cannabis-industry-research/news/15770819/intercure-cannasoul-partner-to-advance-cannabis-science-pharmaceutical-innovation
[GlobeNewswire, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation | https://www.globenewswire.com/news-release/2025/11/03/3179258/0/en/InterCure-and-Cannasoul-Sign-Strategic-Investment-and-Collaboration-Agreements-to-Advance-Cannabis-Science-and-Pharmaceutical-Innovation.html
[Yahoo Finance, Nov 2025] InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation | https://finance.yahoo.com/news/intercure-cannasoul-sign-strategic-investment-133000283.html
[StockTitan, Nov 2025] INCR Stock Price, News & Analysis: Intercure | https://www.stocktitan.net/overview/INCR/
[Markets Insider, Apr 2020] Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm | https://markets.businessinsider.com/news/stocks/eybna-and-cannasoul-top-cannabis-r-d-firms-join-forces-to-prove-a-proprietary-terpene-formulation-for-treating-viral-infections-via-modulation-of-cytokine-storm-1029119056
[Health Europa, Jul 2020] Successful initial results using cannabis terpenes to treat COVID-19 | https://www.healtheuropa.eu/successful-initial-results-using-cannabis-terpenes-to-treat-covid-19/101986/
[Forbes, Jul 2020] New Research Suggests Terpenes And CBD Work 2X's Better For Covid-19 Inflammation Than Corticosteroid | https://www.forbes.com/sites/emilyearlenbaugh/2020/07/21/new-research-suggests-terpenes-and-cbd-work-3xs-better-for-covid-19-inflammation-than-corticosteroid/
[Terpenes and Testing Magazine, Apr 2020] Eybna and CannaSoul join forces on terpene formulation for viral infections | https://terpenesandtesting.com/eybna-and-cannasoul-top-cannabis-rd-firms-join-forces-to-prove-a-proprietary-terpene-formulation-for-treating-viral-infections-via-modulation-of-cytokine-storm/
[GC Intelligence] Professionally Cannabis Podcast: Dr. David (Dedi) Meiri, Technion and CannaSoul | https://contenthub.gcintelligence.com/professionally-cannabis-podcast-dr-david-dedi-meiri-technion-israel-institute-of-technology-cannasoul/
[StreetInsider] Synaptogenix Acquires Significant Stake in Cannasoul Analytics Ltd. Co-founded by The Technion | https://www.streetinsider.com/PRNewswire/Synaptogenix+Acquires+Significant+Stake+in+Cannasoul+Analtyics+Ltd.+Co-founded+by+The+Technion+-+Israel+Institute+of+Technology/22351489.html
[Crunchbase] Venture Round - CannaSoul Analytics | https://www.crunchbase.com/funding_round/cannasoul-analytics-series-unknown--789a4299
[Neoteryx] Cannabis R&D in Pre-Clinical, Clinical Trials, Pharmacokinetic | https://www.neoteryx.com/canna-soul-laboratory
[Labguru] MyPlant Bio cell-based screening models | (publisher reference)
[ISRAC] Cannasoul R&D Ltd. accreditation 473 | https://www.israc.gov.il/?pg=lab&categoryid=246&articleid=271
[Eybna] NT-VRL Terpene Formulation | https://staging.eybna.com/nt-vrl-terpene-formulation/
[PitchBook, 2025] Cannasoul Analytics Company Profile | https://pitchbook.com/profiles/company/491282-74
Articles about Cannasoul R&D Ltd.
- Cannasoul Is Putting an Israeli Cannabis Lab Behind a Push to Treat Real Disease — With InterCure taking up to 51%, the Technion spinout is betting evidence-based therapeutics can move cannabis out of wellness and into the clinic.